Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports.

Cytokinetics, Incorporated announced the granting of stock options and restricted stock units (RSUs) to nine new employees on December 31, 2024, as part of their employment inducement. The company ...